Bayer reports November 3 results: Bayer stock sits 17.40 percent below its high

Published on 10/13/2026 at 14:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter sales rose 2.20 percent to EUR 10.87 billion. Bayer stock costs EUR 44.54 on October 13, 2026, up 1.62 percent versus the Xetra close.

Array

Isometrischer 3D-Render: moderner Pharmaforschungscampus mit transparenten Glasgebäuden auf mehreren Etagen, begrünten Dachterrassen, Fußwegen mit Miniaturpersonen in weißen Kitteln — Isometrische 3D-Render-Illustration eines modernen Pharmaforschungscampus mit Glasgebäuden, Grünflächen und Miniaturpersonen, Illustration mit AI erstellt.

Bayer will publish its third-quarter report on November 3, 2026, according to Borse Express on October 6, 2026. Bayer stock was trading at EUR 44.54 at Lang & Schwarz on October 13, 2026 at 2:22 p.m. CEST, up 1.62 percent versus the Xetra close of October 12, 2026 and 17.40 percent below its 52-week high of EUR 53.92.

Second-quarter sales reached EUR 10.87 billion

Bayer reported second-quarter sales of EUR 10.872 billion, an increase of 2.20 percent after currency and portfolio adjustments, according to Borse Express on September 17, 2026. Adjusted EBITDA before special items rose 1.90 percent to EUR 2.144 billion in the same quarter, giving the upcoming report a clear operating benchmark.

The quarterly report date matters because the November publication will show whether the seasonal timing effects described for Crop Science have passed through the business. The scheduled date is within 45 days of October 13, 2026, keeping the next results release as the nearest concrete company event.

Stock remains below its yearly high

The current EUR 44.54 price stands between Bayer's 52-week low of EUR 25.78 and high of EUR 53.92, both as of October 13, 2026. The distance to the high is 17.40 percent, while the distance to the low is 72.77 percent, placing the stock materially closer to its upper end than to its lower end.

Bayer's investor materials describe three operating businesses: Pharmaceuticals, Consumer Health and Crop Science. The combination links the November reporting date to both prescription medicines and agricultural demand, while the latest sales comparison shows that the second-quarter base was growing rather than contracting.

Valuation and peer comparison

Bayer's market capitalization was EUR 43.8 billion and its P/E ratio was -25.34 as of October 13, 2026. The negative ratio reflects the earnings denominator used by the market data snapshot, so the scheduled report remains more informative than a conventional earnings multiple for the next valuation update.

Comparison with peers

Bayer (Xetra, EUR): plus 1.62 percent, P/E -25.34, market capitalization EUR 43.8 billion
BASF (Xetra, EUR): minus 0.12 percent, P/E 7.69, market capitalization EUR 44.2 billion
Merck KGaA (Xetra, EUR): plus 0.72 percent, P/E 25.63, market capitalization EUR 60.7 billion

Price and upcoming results date

The Xetra close of October 12, 2026 was EUR 43.83. Bayer stock was trading at EUR 44.54 at Lang & Schwarz on October 13, 2026 at 2:22 p.m. CEST, up 1.62 percent versus that Xetra close.

The further course of trading is shown by the continuously updated real-time quote of Bayer stock.